Randomized, Double-blind, Multi-center Study Comparing MCC to BCG as First Line Immunotherapy in Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Recurrence or Progression.
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 27 Oct 2014
At a glance
- Drugs Mycobacterium cell wall DNA complex (Primary) ; BCG
- Indications Bladder cancer
- Focus Therapeutic Use
- Sponsors Endo Pharmaceuticals; Telesta Therapeutics
- 28 Jan 2011 This trial was withdrawn prior to enrollment according to the ClinicalTrials.gov record.
- 28 Jan 2011 New trial record